Average Co-Inventor Count = 9.69
ph-index = 13
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Forma Therapeutics, Inc. (25 from 125 patents)
2. Genentech, Inc. (7 from 3,224 patents)
3. Valo Health, Inc. (7 from 29 patents)
4. Forma Tm, LLC (7 from 10 patents)
5. Novo Nordisk Healthcare Ag (5 from 88 patents)
6. Forma Tm2, Inc. (4 from 4 patents)
7. Agennix USA Inc. (3 from 3 patents)
8. Other (2 from 832,912 patents)
9. Valo Early Discovery, Inc. (2 from 15 patents)
10. Microdose Therapeutx, Inc. (1 from 51 patents)
11. Gpc Biotech, Inc. (1 from 13 patents)
12. Gpc Biotech Ag (1 from 6 patents)
57 patents:
1. 12336981 - Compounds and compositions for the inhibition of NAMPT
2. 12275715 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
3. 12162888 - Carboxamides as ubiquitin-specific protease inhibitors
4. 12128035 - Activating pyruvate kinase R
5. 12071440 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
6. 12053458 - Treating sickle cell disease with a pyruvate kinase R activating compound
7. 12043623 - Purinones as ubiquitin-specific protease 1 inhibitors
8. 11980611 - Treating sickle cell disease with a pyruvate kinase R activating compound
9. 11844787 - Activating pyruvate kinase R
10. 11649242 - Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
11. 11547701 - Compounds and compositions for the inhibition of NAMPT
12. 11524966 - Carboxamides as ubiquitin-specific protease inhibitors
13. 11498913 - Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
14. 11479564 - Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (NAMPT)
15. 11325917 - Thienopyrazine carboxamides as ubiquitin-specific protease inhibitors